Abstract
4556Background: CABOSUN (NCT01835158), a randomized, open-label phase II trial, demonstrated significant improvement in progression-free survival with Cabo (8.6 months) versus Sun (5.3) months) in ...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
